Erratum: HER 2/neu protein expression in gastric cancer is associated with poor survival (Molecular Medicine Reports (2009) 2 (943-946) DOI: 10.3892/mmr-00000196);HER 2/neu protein expression in gastric cancer is associated with poor survival

Molecular Medicine Reports

Volumn 2, Issue 6, 2009, Pages 943-946

  Xie, S D ^a   Xu, C Y ^a   Shen, J G ^a   Jiang, Z N ^a   Shen, J Y ^a   Wang, L B ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Gastric cancer; HER 2 neu; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; UNIVARIATE ANALYSIS;

EID: 73649096906     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3955     Document Type: Erratum

References (21)

1. Hohenberger P and Gretschel S: Gastric cancer. Lancet 362: 305-315, 2003.
2. Green D, Ponce de Leon S, Leon-Rodriguez E and Sosa-Sanchez R: Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival. Am J Clin Oncol 25: 84-89, 2002.
3. Msika S, Benhamiche AM, Jouve JL, Rat P and Faivre J: Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer 36: 390-396, 2000.
4. Kim SY, Kim HP, Kim YJ, et al: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER 2 amplification synergistically with cisplatin. Int J Oncol 32: 89-95, 2008.
5. Gong SJ, Jin CJ, Rha SY and Chung HC: Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 214: 215-224, 2004.
6. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K and Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59: 795-805, 2007.
7. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18: 2201-2209, 2000.
8. Uchino S, Tsuda H, Maruyama K, et al: Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 72: 3179-3184, 1993.
9. Mizutani T, Onda M, Tokunaga A, Yamanaka N and Sugisaki Y: Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 72: 2083-2038, 1993.
10. Tanner M, Hollmen M, Junttila TT, et al: Amplification of HER 2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005.
11. Hilton DA and West KP: c-erbB-2 oncogene product expression and prognosis in gastric carcinoma. J Clin Pathol 45: 454-456, 1992.
12. Kolodziejczyk P, Yao T, Oya M, Nakamura S, Utsunomiya T, Ishikawa T and Tsuneyoshi M: Long-term follow-up study of patients with gastric adenomas with malignant ransformation. An immunohistochemical and histochemical analysis. Cancer 74: 2896-2907, 1994.
13. Akiyama T, Sudo C, Ogawara H, Toyoshima K and Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646, 1986.
14. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985.
15. Sakai K, Mori S, Kawamoto T, et al: Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 77: 1047-1052, 1986.
16. Hofmann M, Stoss O, Shi D, Büttner R, et al: Assessment of a HER 2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008.
17. Gravalos C and Jimeno A: HER 2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529, 2008.
18. Matsubara J, Yamada Y, Hirashima Y, et al: Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER 2 expression on outcomes of patients with gastric cancer. Clin Cancer Res 14: 3022-3029, 2008.
19. Park DI, Yun JW, Park JH, et al: HER 2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51: 1371-1379, 2006.
20. Tateishi M, Toda T, Minamisono Y, et al: Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. Surg Oncol 49: 209-212, 1992.
21. Sasano H, Date F, Imatani A, et al: Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 24: 584-589, 1993.